Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism

PharmacoEconomics

Volumn 12, Issue 1, 1997, Pages 17-29

  Anderson, David R ^a,b   O'Brien, Bernie J ^c,d  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DEXTRAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; ECONOMIC EVALUATION; GENERAL SURGERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LANGUAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

EID: 0030839757     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712010-00003     Document Type: Review

References (38)

1. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994; 36: 417-22
2. Anderson FA, Wheeler HB, Goldberg JP, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-8
3. Clagett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995; 108 Suppl.: 312S-26S
4. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73
5. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108 Suppl.: 335S-51S
6. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81
7. Koopman MMW, Prandoni P, Privella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996; 334: 682-7
8. Salzman EW, Daview GC. Prophylaxis of venous thromboembolism: analysis of cost effectiveness. Ann Surg 1980; 191: 207-15
9. Hull RD, Hirsh J, Sackett DI, et al. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982; 127: 990-5
10. Oster G, Tuden R, Colditz GA. A cost-effective analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203-8
11. Bergqvist D, Jendteg S, Lindgren B, et al. The economics of general thromboemholic prophylaxis. World J Surg 1988; 12: 349-55
12. Bergqvist D, Matzsch T, Jendteg S, et al. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand Suppl 1990; 556: 36-41
13. Hillson SD, Rich EC. Prophylaxis of fatal postoperative pulmonary embolism. Intl J Technol Assess Health Care 1990; 6: 470-9
14. Paiement GD, Wessinger SJ, Harris WH. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg 1991; 161: 519-24
15. Hauch O, Khattar SC, Jorgensen LN. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost 1991; 17 Suppl. 3: 280-3
16. Bergqvist D, Matzsch T. Cost/benefit aspects on thromboprophylaxis. Haemostasis 1993; 23 Suppl. 1: 15-9
17. Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-12
18. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994; 150; 1083-90
19. Drummond M, Aristides M, Davies L, et al. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1742-6
20. Bergqvist D. Cost-effectiveness of venous thromboembolism prophylaxis in surgery. Eur J Surg 1994; 160 Suppl. 571: 49-53
21. Borris LC, Lassen MR, Jensen HP, et al. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Int J Clin Pharmacol Ther 1994; 32: 262-8
22. Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-64
23. Rooke RW, Osmundson PJ. Heparin and the in-hospital management of deep venous thrombosis: cost considerations. Mayo Clin Proc 1986; 61: 198-204
24. Udvarhelyi S, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 1992; 116: 238-44
25. Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendations using level s of evidence for antithrombotic agents. Chest 1995; 108 Suppl.: 227S-30S
26. Lensing AWA, Prandoni P, Buller HR, et al. Lower extremity venography with iohexol: results and complications. Radiology 1990; 177: 503-5
27. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108 Suppl.: 231S-46S
28. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for the prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65
29. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin vs standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6
30. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6
31. The RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg - American Volume 1994; 76: 1174-85
32. Wells PS, Lensing AWA, Davidson BL, et al. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. Ann Intern Med 1995; 122: 47-53
33. 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989; 62: 830-4
34. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
35. Hommes DW, Bura A, Mazzolai L, et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 1992; 116: 279-84
36. Gallus A, Jackaman J, Tillet J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2: 1293-96
37. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4
38. Lensing AWA, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-7